Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton(Baylor College of Medicine), Jenny C. Chang(Universität Hamburg), Michael T. Lewis(Baylor College of Medicine), Xiaping He(University of North Carolina at Chapel Hill), Helen Wong(Baylor College of Medicine), Veronique Neumeister(Yale University), Charles M. Perou(University of North Carolina at Chapel Hill), Ashley B. Sjolund(Yale University), Lorna Renshaw(NHS Lothian), Susan G. Hilsenbeck(Baylor College of Medicine), Dana Faratian(Western General Hospital), Jason I. Herschkowitz(Baylor College of Medicine), Anne C. Pavlick(Baylor College of Medicine), Alexey A. Larionov(NHS Lothian), Jeffrey M. Rosen(Baylor College of Medicine), Angel Rodriguez(Baylor College of Medicine), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Xiaoxian Li(Emory University), Cheng Fan(University of North Carolina at Chapel Hill), Maya Gutierrez(Baylor College of Medicine), J. Michael Dixon(University of Colorado Denver), Melissa D. Landis(Baylor College of Medicine), David L. Rimm(Yale University)
Cited by 1,383
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k